US safety concerns delay Astellas/Cardiome's Kynapid
This article was originally published in Scrip
Executive Summary
A new clinical trial could be required for approval of Astellas/Cardiome Pharma's novel atrial fibrillation therapy Kynapid (vernakalant HCl injection) in the US, where FDAconcerns about potential cardiovascular adverse events have delayed licensing.